

Remarks

The Applicants respectfully submit that this preliminary amendment adds no new matter. The specification has been amended to insert a cross-reference to a related application and to correct typographical, grammatical, and numbering errors in the specification (including the sequence listing).

The Applicants request entry of the amended sequence listing enclosed with this amendment. All sequences disclosed in the amended sequence listing are disclosed in the original specification, and thus, no new matter is added through this amendment. However, the originally filed sequence listing contains two inconsistencies with the specification. These inconsistencies are corrected via the amended sequence listing and renumbering of the SEQ ID NOs within the specification.

First, SEQ ID NOs: 189 and 190 are listed as the A277V/P285L/F398I variant in Figure 18 of the specification as originally filed. However, in the original sequence listing these sequences are shown as an A277V/F398I variant, missing the P285L mutation. The amended sequence listing, enclosed herewith, changes nucleotides 853-855 of SEQ ID NO:189 from CCG to CTC, such change being described in Figure 18 of the originally filed specification. The amended sequence listing also changes the corresponding protein, SEQ ID NO:190, according to Figure 18, such that the Pro residue at amino acid position 285 is mutated to Leu. These changes are illustrated herein, *supra*.

Second, the originally filed sequence listing had no sequences listed for SEQ ID NOs:199, 200, or 203. For those sequences, the sequence listing only had three zeroes ("000"). These "dummy" sequences have been removed from the sequence listing, and subsequent sequences in the sequence listing have been renumbered such that all SEQ ID NOs are sequential. In other words, the sequences originally numbered SEQ ID NO:201, 202 and 204 have been renumbered such that they are now SEQ ID NOs:199, 200, and 201, respectively.

Moreover, the specification has been amended to correct the renumbering of these sequences. Changes within the disclosure are illustrated herein, *supra*. An electronic version of the entire amended sequence listing is provided with this amendment.

Bases for new Claims 105-150 are found throughout the original specification. Illustrative references therein are listed in the table below:

New Claim #	Basis
105	Original Claim 1
106	Original Claim 3
107	Original Claim 5
108	Original Claim 15
109	Original Claim 19
110	Original Claim 2
111	Page 20, line 28 through page 21, line 9
112	Page 20, line 28 through page 21, line 9
113	Page 20, line 28 through page 21, line 9
114	Page 20, line 28 through page 21, line 9
115	Page 20, line 28 through page 21, line 9
116	Page 20, line 28 through page 21, line 9
117	Page 20, line 28 through page 21, line 9
118	Page 33, lines 10-21
119	Page 33, lines 10-21
120	Page 33, line 22 through page 34, line 3
121	Page 33, line 22 through page 34, line 3
122	Original Claim 37
123	Original Claims 37-47
124	Original Claim 48
125	Original Claim 50
126	Original Claim 56
127	Original Claim 66
128	Original Claim 49
129	Page 46, line 27 through page 47, line 24
130	Page 46, line 27 through page 47, line 24
131	Page 46, line 27 through page 47, line 24
132	Page 46, line 27 through page 47, line 24
133	Page 46, line 27 through page 47, line 24
134	Page 46, line 27 through page 47, line 24
135	Page 46, line 27 through page 47, line 24
136	Original Claim 68
137	Original Claim 69
138	Original Claim 80
139	Original Claim 81
140	Original Claim 82
141	Original Claim 83
142	Original Claim 84
143	Original Claim 85
144	Original Claim 86
145	Original Claim 98
146	Original Claim 99
147	Original Claim 100
148	Original Claim 101
149	Original Claim 103
150	Original Claim 104

The Applicants respectfully request entry of the amended sequence listing and the amendments to the specification. It is submitted that the claims are of proper scope for allowance, and a favorable action on the merits is respectfully requested. Should the Examiner wish to discuss the foregoing in an effort to advance this application towards allowance, the Examiner is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

Paula K. Davis

Paula K. Davis
Attorney for Applicants
Registration No. 47,517
Phone: 317-433-3422

Eli Lilly and Company
Patent Division/PKD
P.O. Box 6288
Indianapolis, Indiana 46206-6288

May 12, 2005